1.

Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup, SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther. 2004:26(1):35-47.

2.

 Bielory L. Ocular allergy treatments. Clin Rev Allergy Immunol. 2001;20(2):201-213.
3.
 Data on file, Allergan, Inc.; Adult Ocular Allergy Attitudes Evaluation, December 2003.
4.
 Data on file, Inspire Pharmaceuticals, Inc.
5.
 ELESTAT® Prescribing Information.
6.
 Friedlaender M, Scharf L, Brashears D. Control of ocular allergy symptoms by epinastine HCl 0.05% in a conjunctival antigen challenge evaluation. Poster presented at: 8th Winter Refractive Surgery Meeting of the European Society of Cataract and Refractive Surgeons; January 23-25, 2004; Barcelona, Spain.
7.
 Kamei C, Akagi M, Mio M, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol. 1992;14(1-2):191-205.
8.
 Kohyama T, Takizawa H, Akiyama N, Sato M, Kawasaki S, Ito K. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun. 1997;230(1):125-128.
9.
 Matsushita N, Aritake K, Takada A, et al. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. Jpn J Pharmacol. 1998;78(1):11-22.
10.
 Abelson M, Leonardi A, Smith L. The mechanisms, diagnosis and treatment of allergy. Rev Ophthalmol. 2002; 9(4).
11.
 Pflugfelder SC, Villareal AL, Farley W. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Poster presented at: the Annual Meeting of the American College of Allergy, Asthma & Immunology; March 18-22;2005;San Antonio, TX.



©2006 Inspire Pharmaceuticals, Inc., Durham, NC 27703 ® Marks owned by Allergan, Inc. Inspire and the Inspire logo are registered trademarks of Inspire Pharmaceuticals, Inc. ELESTAT® is licensed from Boehringer Ingelheim Pty. Ltd., Ingelheim, Germany.


ELESTAT® ophthalmic solution is indicated for the prevention of ocular itching associated with allergic conjunctivitis.

Important Safety Information:
ELESTAT® ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to epinastine or to any of the other ingredients.

Patients should be advised not to wear a contact lens if their eye is red. ELESTAT® ophthalmic solution should not be used to treat contact lens related irritation. The preservative in ELESTAT®, benzalkonium chloride, may be absorbed by soft contact lenses.Contact lenses should be removed prior to instillation of ELESTAT® ophthalmic solution and may be reinserted after 10 minutes following its administration.

The most frequently reported ocular adverse events occuring in approximately 1% to 10% of patients were burning sensation in the eye, folliculosis, hyperemia, and pruritus. The most frequently reported nonocular adverse events were infection (cold symptoms and upper respiratory infections), seen in approximately 10% of patients, and headache, rhinitis, sinusitis, increased cough, and pharyngitis seen in approximately 1% to 3% of patients. Some of these events were similar to the underlying disease being studied.

Please see prescribing information for ELESTAT®.